AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00964834
Drug: Doxycycline and Valortim
RxNorm normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Days 1-5 100mg IV Doxycycline BID over 60 minutes. Day 6 20mg/kg Valortim IV over 60 minutes.
Trial: NCT00964834
Drug: Placebo Antibiotic and Valortim
RxNorm normalized name: beclometasone and antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Days 1-5 20mg/kg IV Normal Saline BID over 60 minutes. Day 6 20mg/kg IV Valortim over 60 minutes.
Trial: NCT01212822
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT01212822
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00022230
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00022230
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03976687
Drug: EYP001a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablets
Trial: NCT01172496
Drug: treprostinil diethanolamine
RxNorm normalized name: treprostinil 1 MG (as treprostinil diethanolamine) 12 HR Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will be administered a 1 mg dose of treprostinil diethanolamine as a single tablet, and treprostinil diethanolamine oral solution 0.25 mg dose every 2 hours for four doses (1 mg total).
Trial: NCT00005962
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01571999
Drug: Inhaled GSK573719
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All subjects will receive a single dose of GSK573719 (125mcg) in treatment period 1
Trial: NCT01103310
Drug: BAY94-9392
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04074421
Drug: Probiotic Formula
RxNorm normalized name: Probiotic Formula
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A probiotic called Enterococcus faecium, 500mg, triple one day for 4 weeks.
Trial: NCT04074421
Drug: Placebo oral tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo oral tablet that has no therapeutic effect
Trial: NCT01353274
Drug: Micamlo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telmisartan plus Amlodipine T40/A5
Trial: NCT03994705
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Pre-conditioning therapy
Trial: NCT01871493
Drug: LY2605541
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered subcutaneous (SQ)
Trial: NCT03761030
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25/100 placebo tablets
Trial: NCT04445857
Drug: Calcitonin presented as Miacalcic® ampoules 100 IU/ml (1ml) intravenously
FDA approved: no
EMA approved: no
PMDA approved: no
Description: coadministration of calcitonin intravenously and a single-shot hyperbaric bupivacaine
Trial: NCT01858116
Drug: [68Ga]ABY-025
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous injection followed by PET imaging
Trial: NCT01144039
Drug: HG-group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01144039
Drug: Placebo-group
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01844401
Drug: ProAir® HFA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ProAir® HFA 180 mcg (administered as 2 actuations of 90 mcg of albuterol base/actuation ex-mouthpiece) orally inhaled, single dose
Trial: NCT03164564
Drug: Oral TDF/FTC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TDF/FTC 300 mg/200 mg fixed dose combination tablet
Trial: NCT03164564
Drug: Placebo for oral CAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets
Trial: NCT03164564
Drug: Placebo for oral TDF/FTC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets
Trial: NCT03164564
Drug: Placebo for CAB LA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered as one 3 mL intramuscular injection in the gluteal muscle
Trial: NCT00644176
Drug: azithromycin immediate release (Zithromax)
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: azithromycin IR 500 mg tablet by mouth for 1 dose
Trial: NCT00644176
Drug: azithromycin SR
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 2.0 g by mouth in the form of liquid for 1 dose
Trial: NCT03557931
Drug: ASP4345
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral administration
Trial: NCT03557931
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral administration
Trial: NCT02560870
Drug: Active Comparator:Aloe Vera mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mouthwash( Aloe Vera),10 ml by patients routinely washed two times in one day for about 30 seconds for two weeks.
Trial: NCT03372330
Drug: Standard care for sepsis and PAD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The standard medications care for the patient with PAD included antiplatelet agents.
Trial: NCT01656330
Drug: Profilnine SD
RxNorm normalized name: Profilnine SD (obsolete)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single bolus dose of Profilnine SD 50 IU/kg administered by intravenous (IV) injection on Day 5. Interpretation by CTRL: Concentration type = Exact; Number = 50; unit=IU/kg; route: intraveous use.
Trial: NCT01656330
Drug: Beriplex P/N
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single bolus dose of Beriplex P/N 50 IU/kg administered by intravenous (IV) injection on Day 5 Interpretation by CTRL: Concentration type = Exact ; Number = 50; unit=IU/kg; route : intravenous use
Trial: NCT04029701
Drug: Ruyizhenbao Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ruyizhenbao Pills are provided by Jinhe Tibetan Pharmaceutical Co., Ltd. Chinese national medicine permission number:Z63020289、Z63020064. Medication method: oral 4 pills once, twice a day, 4 weeks in a row.
Trial: NCT03292406
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non active ingredients of CD11301
Trial: NCT03292406
Drug: CD11301 0.03%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical Gel
Trial: NCT01676740
Drug: Iron Supplement,
RxNorm normalized name: Iron Supplement, 250 mg oral capsule, extended release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pills to be swallowed
Trial: NCT01676740
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily administration of active drug or placebo
Trial: NCT03292406
Drug: CD11301 0.06%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical Gel
Trial: NCT04029701
Drug: Placebo of Ruyizhenbao Pill
RxNorm normalized name: placebo Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo is provided by Jinhe Tibetan Pharmaceutical Co., Ltd.，which is made of malt dextrin as a matrix, similar shape and same color to the Ruyizhenbao Pill. Medication method: oral 4 pills once, twice a day, 4 weeks in a row.
Trial: NCT00532350
Drug: QAT370
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00532350
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00142779
Drug: Fluoxetine
RxNorm normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01058018
Drug: RVX000222
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RVX000222 twice a day for 12 weeks
Trial: NCT01058018
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo twice a day for 12 weeks
Trial: NCT03048344
Drug: ORH-2014
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ORH-2014 capsule 5 mg orally with dose escalations of 5 mg intervals.
Trial: NCT04393298
Drug: trifluridine/tipiracil
RxNorm normalized name: TRIFLURIDINE/TIPIRACIL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Study participants will receive predefined doses of trifluridine/tipiracil (TFD/TPI) administered as film-coated tablets at pre-specified time points.
Trial: NCT04393298
Drug: mFOLFOX6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Study participants will receive predefined doses of oxaliplatin, Leucovorin and 5-fluorouracil as part of the mFOLFOX6 chemotherapy regimen administered as intravenous (iv) infusion at prespecified time points.
Trial: NCT00309530
Drug: 5-fluorouracil, levamisol, interferon
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02691182
Drug: SPN-810
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00220532
Drug: Folic acid with riboflavin
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00239746
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 200mg taken orally daily for 6-12 weeks
Trial: NCT00239746
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200mg matched placebo taken orally daily for 6-12 weeks
Trial: NCT04558190
Drug: Intralipid, 20% Intravenous Emulsion
RxNorm normalized name: Intralipid, 20% intravenous emulsion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lipid infusion
Trial: NCT00595504
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two week supply of placebo tablets first dispensed at baseline. New two week supply of placebo dispensed at each biweekly visit for 8 consecutive weeks.
Trial: NCT01183208
Drug: Intervention B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single dose of 30 mg will consist of 3 sprays of the 10 mg strength spray applied topically to cervix (1 spray) and vaginal fornices (2 sprays)
Trial: NCT01183208
Drug: Intervention C
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single dose of 150 mg will consist of 15 sprays of the 10 mg strength spray applied topically to cervix (5 sprays) and vaginal fornices (10 sprays)
Trial: NCT00615264
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mannitol (excipient) 40 mg, administered as subcutaneous injection on 1, 3, 6, 9, 12, 15, 18 and 21 months.
Trial: NCT04492358
Drug: standard of care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The standard treatment used in each site will be administered to the patients assigned to the control group.
Trial: NCT01583686
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Days -7 and -6: Cyclophosphamide 60 mg/kg/day X 2 days intravenous (IV) in 250 ml 5% dextrose in water (D5W) with Mesna 15 mg/kg/day X 2 days over 1 hr.
Trial: NCT01538472
Drug: Y Zevalin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Starting dose: 0.4 mCi/kg by vein after Rituxan infusion on Day -14.
Trial: NCT01538472
Drug: In Zevalin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imaging dose: 5 mCi by vein following Rituxan infusion on Day -21.
Trial: NCT00243542
Drug: ACZONE Gel, 5%
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00243542
Drug: Vehicle
RxNorm normalized name: Drug vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04324346
Drug: FEC100 + Taxotere (EC90 + Taxotere) 3+3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Type of Chemotherapy
Trial: NCT00964990
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Form=solution for injection, route=Subcutaneous injection. One injection of matching placebo every 28 days for up to 52 wks
Trial: NCT00369538
Drug: hydrochlorothiazide, losartan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One administration of hydrochlorothiazide, 25 mg per day during 2 months, followed by a wash-out during 1 month, and then, two administrations of losartan per day,up to 100mg per day, during 2 months
Trial: NCT02829723
Drug: BLZ945
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BLZ945 administered orally as a capsule. Up to five alternative dosing schedules were evaluated: once per day (QD) 7 days on/7 days off (i.e., administer BLZ945 for 7 days and suspend for 7 days), QD 4 days on/10 days off, twice per day (BID) 4 days on/10 days off, once weekly (Q1W) QD and Q1W BID.~Each cycle consisted of 28 days.
Trial: NCT02829723
Drug: PDR001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PDR001 400 mg administered via intravenous (i.v.) infusion every 4 weeks (Q4W)
Trial: NCT01361425
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo 500mg 8/8h, orally
Trial: NCT01701414
Drug: Placebo: 3cc of 0.9% Normal Saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1cm lateral to the ultrasound probe, a 27 gauge needle and syringe will be used to inject 3cc of 0.9% NS subcutaneously. The SC group will then be cared for by the Emergency Department physicians according to their regular clinical practice
Trial: NCT03340961
Drug: DFD-29 Extended Release Capsules (40 mg)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Treatment
Trial: NCT03340961
Drug: DFD-29 Extended Release Capsules (20 mg)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Treatment
Trial: NCT03340961
Drug: Oraycea® (doxycycline) Capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Treatment
Trial: NCT03340961
Drug: Placebo Capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Treatment
Trial: NCT01010295
Drug: doxycycline (tetracycline)
RxNorm normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: doxycycline 100 mg twice daily for 3 weeks
Trial: NCT02856113
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alogliptin placebo-matching tablets.
Trial: NCT01116609
Drug: Epinephrine
RxNorm normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: unilateral leg infusion of Epinephrine 0.4 micrograms/m2/min
Trial: NCT00114179
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given orally
Trial: NCT04890535
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: matching placebo oral suspension for TBAJ-587
Trial: NCT02827201
Drug: FOLFIRI.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For each cycle : 1 week out of 2 - injection at Day1, J15 Irinotécan 90 mg/m² at day1 in perfusion over 60 min in Y of folinic acid Folinic Acid 400 mg/m² (or 200 mg/m² Elvorine) at Day 1 in perfusion over 2 hours 5FU continu 2000 mg/m² during 46 hours Irinotécan at 90 mg/m² in perfusion over 60 mn at Day 3 (when 5FU perfusion is over)
Trial: NCT00620854
Drug: Nasal Spray
RxNorm normalized name: Nasal Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 IU recombinant salmon calcitonin, single intranasal spray
Trial: NCT03137784
Drug: NVA237 (glycopyrronium bromide)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In each treatment arm, patient will receive NVA237 (glycopyrronium bromide) 25 ug and 50 ug dose
Trial: NCT01700075
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lipidlowering: Atorvastatin (Liprimar) - 40mg per day. Antihypertensive: Diroton (Lisinopril, Gedeon Richter Ltd) - 10mg twice per day and Ditiazem (calcium bloker from the benthodiazepines, Lannacher, Austria) - 90mg per day.~Antihyperglycemic drugs: biguanides Metformin - 0.5 g two or tree times per day, or Exenatide - 5-10 µg per day.~Anti-inflammatory: TromboACC (acetylsalicylate acid) up to 2 g per day and/or Clopidogrel (thienopyridine class antiplatelet agent) - 75mg per day.
Trial: NCT02132845
Drug: targeted therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Receive target-directed therapy
Trial: NCT00415792
Drug: Arvekap, Pregnyl
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03067688
Drug: Temisartan+Amlodipine+Rosuvastatin (Combination drug)
RxNorm normalized name: amlodipine / telmisartan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PO, Once daily(QD), 8weeks
Trial: NCT03067688
Drug: Temisartan+Rosuvastatin
RxNorm normalized name: rosuvastatin and telmisartan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PO, Once daily(QD), 8weeks
Trial: NCT00154778
Drug: Taxol, UFT,Leucovorin
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03432793
Drug: Caffeine
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral solution, single dose
Trial: NCT02076893
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Both study arms will receive as needed (PRN) ibuprofen to take home.
Trial: NCT02076893
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simple syrup suspension
Trial: NCT03342261
Drug: DAA treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients were treated with direct-acting antiviral (DAA) treatment for 12 or 24 weeks
Trial: NCT04459715
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matched placebo administrated as oral solution from Day 1 to 14, every 21-day cycle.
Trial: NCT01855217
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0,9% NaCl
Trial: NCT02831257
Drug: AZD2014
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03163914
Drug: Epinephrine
RxNorm normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Epinephrine infusion rate will adjust 30 ml/h (5µg/ ml )
Trial: NCT03163914
Drug: Norepinephrine
RxNorm normalized name: Norepinephrine
DrugBank: Norepinephrine (DB00368)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Norepinephrine infusion rate will adjust 30 ml/h (5µg/ ml )
Trial: NCT02343445
Drug: P-1037
RxNorm normalized name: P
FDA approved: no
EMA approved: no
PMDA approved: no
Description: P-1037 is a novel ENaC inhibitor
Trial: NCT02343445
Drug: Hypertonic Saline
RxNorm normalized name: ENTSOL Hypertonic Saline Nasal Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4.2% saline solution
Trial: NCT00890084
Drug: Telmisartan or Telmisartan + Hydrochlorothiazide (HCTZ)
RxNorm normalized name: hydrochlorothiazide / telmisartan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telmisartan 40mg or 80mg +/- HCTZ 12.5mg or 25mg
Trial: NCT03184194
Drug: nivolumab-daratumumab with low-dose cyclophosphamide
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: nivolumab-daratumumab with low-dose cyclophosphamide will be given until progression
Trial: NCT03340220
Drug: XPF-008
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule filled with XEN1101
Trial: NCT03340220
Drug: XPF-010
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule filled with XEN1101
Trial: NCT03075891
Drug: Doxycycline 40 mg MR (30 mg Immediate Release & 10 mg Delayed Release beads) capsules
RxNorm normalized name: doxycycline
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 Capsule once-daily for 12 weeks
Trial: NCT04053140
Drug: Penicillin G_600mg/hr
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benzylpenicillin IV administered in continuous dosing schedule. Dosage to be determined by closed-loop algorithm. Initial loading dose, and limits set to 600mg/hr.
Trial: NCT00295035
Drug: CELECOXIB
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00780793
Drug: DMARD maintenance
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DMARD maintenance
Trial: NCT00298922
Drug: Azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 500 mg tablets orally thrice weekly for 24 weeks
Trial: NCT00298922
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tablet orally thrice weekly for 24 weeks
Trial: NCT00916461
Drug: Minocycline
RxNorm normalized name: Minocycline
DrugBank: Minocycline (DB01017)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Minocycline + treatment as usual. 50 mg twice daily increasing to 200 mgs per day, increments of 50 mgs every 2 weeks.
Trial: NCT00916461
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo + treatment as usual.
Trial: NCT00560612
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo: same as paroxetine (active comparator)
Trial: NCT04241458
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT01856530
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matched placebo nasal spray
Trial: NCT03995108
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matching to mavorixafor capsules
Trial: NCT00643409
Drug: azithromycin SR (Zithromax; compound: CP-62,993)
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Azithromycin SR 2.0 g by mouth in the form of a slurry x 1 dose
Trial: NCT02726711
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 - 4.0 mg IV to be infused
Trial: NCT01107808
Drug: Calcium and Vit D
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ergocalciferol (vitamin D2) treatment 50,000 IU orally, weekly for 8 weeks calcium carbonate orally 1200mg daily